US Patent 9505745 Enhancer of zeste homolog 2 inhibitors
Patent 9505745 was granted and assigned to GlaxoSmithKline on November, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 5 Dec, 2023
Golden AI
Edits made to:
Article (+283 characters)
Article
Patent abstract
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+13 properties)
Infobox
Patent Inventor Names
Charles William Blackledge, Jr.0
Dai-Shi Su0
Jiri Kasparec0
Joelle Lorraine Burgess0
Juan I. Luengo0
Kenneth Allen Newlander0
Louis V. LaFrance, III0
Mark Schulz0
Neil W. Johnson0
Steven David Knight0
Stuart Paul Romeril0
William Henry Miller0
Xinrong Tian0
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09505745 Enhancer of zeste homolog 2 inhibitors US Patent 9505745 Enhancer of zeste homolog 2 inhibitors
Infobox
Patent Number
09505745
Patent Number
9505745
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09505745 Enhancer of zeste homolog 2 inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09505745
Date of patent
November 29, 2016
Patent application number
14787866
Date Filed
April 25, 2014
Patent primary examiner
Find more entities like US Patent 9505745 Enhancer of zeste homolog 2 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.